Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

2020/03/26 by Ryan Choi, Matthew A. Hulverson, Wenlin Huang +27 · 26 citations
Medicine · Veterinary · #Trypanosoma species research and implications #Research on Leishmaniasis Studies #Helminth infection and control

paper · pdf · doi:10.1016/j.ijpara.2020.01.006

Cited by

• An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii
• Neospora caninum : Differential Proteome of Multinucleated Complexes Induced by the Bumped Kinase Inhibitor BKI-1294. [europepmc]
• A Conditional Protein Degradation System To Study Essential Gene Function in Cryptosporidium parvum. [europepmc]
• Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis. [europepmc]
• The Impact of BKI-1294 Therapy in Mice Infected With the Apicomplexan Parasite Neospora caninum and Re-infected During Pregnancy. [europepmc]
• A framework for signaling throughout the life cycle of Babesia species. [europepmc]
• Use-case scenarios for an anti-Cryptosporidium therapeutic. [europepmc]
• In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts. [europepmc]
• Emerging treatment options for cryptosporidiosis. [europepmc]
• Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin. [europepmc]
• A short-term treatment with BKI-1294 does not protect foetuses from sheep experimentally infected with Neospora caninum tachyzoites during pregnancy. [europepmc]
• Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor in Neospora caninum and Danio rerio . [europepmc]
• High-Throughput Screening of a Marine Compound Library Identifies Anti- Cryptosporidium Activity of Leiodolide A. [europepmc]
• An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives. [europepmc]
• Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining the Listeria monocytogenes -Based Vaccine Lm3Dx_NcSAG1 With the Bumped Kinase Inhibitor BKI-1748 Against Neospora caninum Infection in Mice. [europepmc]
• The Marine Compound Tartrolon E Targets the Asexual and Early Sexual Stages of Cryptosporidium parvum . [europepmc]
• Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis. [europepmc]
• Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633. [europepmc]
• Single and combination treatment of Toxoplasma gondii infections with a bumped kinase inhibitor and artemisone in vitro and with artemiside in experimentally infected mice. [europepmc]
• Anti-Cryptosporidial Drug-Discovery Challenges and Existing Therapeutic Avenues: A "One-Health" Concern. [europepmc]
• Genomic and virulence analysis of in vitro cultured Cryptosporidium parvum. [europepmc]
• Molecular Targets of the 5-Amido-Carboxamide Bumped Kinase Inhibitor BKI-1748 in Cryptosporidium parvum and HCT-8 Host Cells. [europepmc]
• Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for Cryptosporidium. [europepmc]
• Efficacy of the bumped kinase inhibitor BKI-1708 against the cyst-forming apicomplexan parasites Toxoplasma gondii and Neospora caninum in vitro and in experimentally infected mice. [europepmc]
• Treatment with BKI-1748 after Toxoplasma gondii systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection. [europepmc]
• Bumped Kinase Inhibitors Inhibit both Toxoplasma gondii MAPKL1 and CDPK1. [europepmc]